MDT
86.14
-0.25%↓
A
114.53
+0.54%↑
VEEV
172.83
-1.41%↓
HQY
83.37
+0.23%↑
PHR.US
8.39
+0.72%↑
MDT
86.14
-0.25%↓
A
114.53
+0.54%↑
VEEV
172.83
-1.41%↓
HQY
83.37
+0.23%↑
PHR.US
8.39
+0.72%↑
MDT
86.14
-0.25%↓
A
114.53
+0.54%↑
VEEV
172.83
-1.41%↓
HQY
83.37
+0.23%↑
PHR.US
8.39
+0.72%↑
MDT
86.14
-0.25%↓
A
114.53
+0.54%↑
VEEV
172.83
-1.41%↓
HQY
83.37
+0.23%↑
PHR.US
8.39
+0.72%↑
MDT
86.14
-0.25%↓
A
114.53
+0.54%↑
VEEV
172.83
-1.41%↓
HQY
83.37
+0.23%↑
PHR.US
8.39
+0.72%↑
24h
Actual
Mínimo
18.89
Máximo
19.66
Ingresos | -86M -120M |
|---|---|
Ventas | -70M 132K |
BPA | -1.08 |
Margen de beneficios | -91,178.03 |
Empleados | 252 |
EBITDA | -80M -114M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +85.43% upside |
Próximas Ganancias | 5 may 2026 |
|---|
Capitalización Mercado | 144M 2.8B |
|---|---|
Apertura anterior | 21.56 |
Cierre anterior | 19.05 |
By Acuity
20%
80%
49 / 349 Clasificación en Healthcare
By Trading Central
Confianza
Very Strong Bearish Evidence
12 / 13.14 Soporte y Resistencia
Resultados pasados no son un indicador fiable de resultados futuros.
31 mar 2026, 23:31 UTC
Stocks to Watch: Nike, RH, NCino
DJ
Leer
31 mar 2026, 22:35 UTC
Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update
DJ
Leer
1 abr 2026, 00:00 UTC
The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ
DJ
Leer
31 mar 2026, 23:50 UTC
Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO
DJ
Leer
31 mar 2026, 23:43 UTC
Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk
DJ
Leer
31 mar 2026, 23:33 UTC
Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk
DJ
Leer
31 mar 2026, 23:21 UTC
Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com
DJ
Leer
31 mar 2026, 23:14 UTC
Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk
DJ
Leer
31 mar 2026, 23:12 UTC
Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk
DJ
Leer
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss Widens >000002.SZ
DJ
Leer
31 mar 2026, 22:36 UTC
China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ
DJ
Leer
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ
DJ
Leer
31 mar 2026, 22:36 UTC
China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ
DJ
Leer
31 mar 2026, 22:36 UTC
China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ
DJ
Leer
31 mar 2026, 21:46 UTC
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
DJ
Leer
31 mar 2026, 21:36 UTC
West African Resources's Costs Higher Than Bull Expected -- Market Talk
DJ
Leer
31 mar 2026, 21:35 UTC
Nike Expects China Sales Down 20% in 4Q, CFO Says
DJ
Leer
31 mar 2026, 21:35 UTC
Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says
DJ
Leer
31 mar 2026, 21:35 UTC
Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says
DJ
Leer
31 mar 2026, 21:33 UTC
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
DJ
Leer
31 mar 2026, 21:33 UTC
Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says
DJ
Leer
31 mar 2026, 21:32 UTC
Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says
DJ
Leer
31 mar 2026, 21:28 UTC
Nike Expects to End 4Q With Elevated Inventory, CFO Says
DJ
Leer
31 mar 2026, 21:26 UTC
Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says
DJ
Leer
31 mar 2026, 21:25 UTC
Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says
DJ
Leer
31 mar 2026, 21:24 UTC
Nike: Turnaround Plan Progressing at Different Rates -- Market Talk
DJ
Leer
31 mar 2026, 21:22 UTC
Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters
DJ
Leer
31 mar 2026, 21:22 UTC
Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says
DJ
Leer
31 mar 2026, 21:21 UTC
Nike's Digital Channel Still Too Promotional, CFO Says
DJ
Leer
31 mar 2026, 21:20 UTC
Nike CEO: Converse Remains Important to Portfolio
DJ
Leer
Cambio de precio
By TipRanks
Estimación a 12 Meses
Media 36.27 USD 85.43%
Máximo 50 USD
Mínimo 20 USD
De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para VIRIDIAN THERAPEUTICS INC Dist en los últimos 3 meses.
By TipRanks
Compra Fuerte
13 ratings
12
Comprar
1
Mantener
0
Vender
De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para VIRIDIAN THERAPEUTICS INC Dist en los últimos 3 meses.
By Trading Central
Corto Plazo
Very Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Medio plazo
Bearish Evidence
All events are bearish.
Largo Plazo
Strong Bearish Evidence
All events are bearish.
By Acuity
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Media
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$